Ventricular Tachycardia | Fibrillatory Factor in Ventricular Tachycardia
Ventricular Tachycardia research study
What is the primary objective of this study?
This study involves recording electrical signals inside the heart during an ablation procedure. It is thought that by studying these electrical signals in detail the investigators may be able to better identify and treat patients at risk of Ventricular Tachycardia (VT). VT is where the lower chambers (ventricles) of your heart beat fast and this condition can be life-threatening. An ablation procedure is performed in patients who have VT despite the best treatment available with tablets. Cardiac ablation involves interrupting the abnormal electrical signals, which cause VT, by applying a type of electrical energy through a catheter. An important part of the ablation procedure is the identification of the exact part of the heart muscle responsible for causing the VT. This typically involves sampling the electrical signals in lots of different areas of the heart, which allows the construction of computer generated 3 dimensional pictures of the structure and the electrical circuits inside the ventricle. Recent research has identified a new method to interpret these electrical signals (called Fibrillatory Factor - FF), which may allow better identification of the area within the ventricle that should be ablated. A standard VT ablation will often involve us controlling the heart-beat by pacing the heart through 1 of the investigators catheters within the heart. The electrical response to pacing at different heart rates can often provide your doctor with information to help the ablation. This study will involve an additional period of pacing at different heart rates, during which the electrical response is measured in different areas around the ventricle. This will allow us to calculate areas of the ventricle, which the investigators new measure FF would predict to be the source of the VT. In the future this may then allow us to better identify patients who are at risk of VT, and to better locate the area that needs to be ablated.
Who is eligible to participate?
Inclusion Criteria: - Age 18 or above, and capable of giving informed consent - Scheduled for a clinically indicated cardiac ablation for the treatment of ventricular tachycardia Exclusion Criteria: - Moderate or severe aortic stenosis or mitral stenosis - Active infection - Presence of thrombus, cardiac tumour, interatrial Baffle patch (a specific form of congenital cardiac surgery) or prior septal occluder device - Subjects who cannot be anticoagulated of infused with heparinized saline - A history of heparin induced thrombocytopenia - Pregnant or actively breast feeding
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Procedure:Fibrillatory Factor calculation (FF)During sinus rhythm these patients will undergo a simple pacing protocol to allow us to calculate FF, which is an area we would predict is mod likely to be the origin of their VT.
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Ventricular Tachycardia (VT)Patients with VT will undergo a clinically indicated ablation of their VT
Start Date: November 2013
Primary Outcome: Fibrillatory Factor
Secondary Outcome: Real-time fibrillatory factor
Study sponsors, principal investigator, and references
Principal Investigator: Jaswinder Gill, MD
Lead Sponsor: Guy's and St Thomas' NHS Foundation Trust